Skip to search formSkip to main contentSkip to account menu

deferiprone

Known as: 1,2-dimethyl-3-hydroxypyrid-4-one, DMOHPO, 1,2-dimethyl-3-hydroxypyridin-4-one 
An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to… 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (3)

CP20 (deferiprone)FerriproxPL-1
Iron Chelating Activity [MoA]deferiprone 500 MG Oral Tablet [Ferriprox]

Broader (2)

Iron Chelating AgentsPyridones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Chelation in metal intoxication--Principles and paradigms.
Highly Cited
2011
Highly Cited
2011
Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
Review
2010
Review
2010
Sickle cell disease and the eye: old and new concepts.
Highly Cited
2009
Highly Cited
2009
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
Objective:  Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor… 
Review
2007
Review
2007
Metals ions and neurodegeneration
Neurodegenerative disorders include a variety of pathological conditions, which share similar critical metabolic processes such… 
Review
2006
Review
2006
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation… 
Review
2003
Review
2003
Role of deferiprone in chelation therapy for transfusional iron overload.
Before 1987, iron chelation therapy for patients with thalassemia major and other refractory anemias requiring regular… 
Highly Cited
2002
Highly Cited
2002
The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients
Summary. In 1997, the Italian Ministry of Health created a special programme for the controlled distribution of deferiprone to… 
Highly Cited
2001
Highly Cited
2001
Chelation therapy in β-thalassemia: An optimistic update☆
Highly Cited
1996
Highly Cited
1996
Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)